Novartis Exelon
Executive Summary
Additional clinical trials analyses were submitted by Novartis in December in response to a July request by FDA. No further clinical trials were requested. The cholinesterase inhibitor rivastigmine for the treatment of Alzheimer's disease has been pending at the agency since April 7, 1997